Aurinia Pharmaceuticals Inc (AUPH) Lowered to “Hold” at Vetr Inc.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was downgraded by Vetr from a “buy” rating to a “hold” rating in a research note issued on Wednesday. They presently have a $6.64 target price on the biotechnology company’s stock. Vetr‘s price objective would suggest a potential downside of 1.48% from the company’s current price.
AUPH has been the subject of a number of other research reports. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Cantor Fitzgerald set a $14.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Tuesday, August 15th. Finally, HC Wainwright cut their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $9.71.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 2.32% during mid-day trading on Wednesday, hitting $6.74. 1,789,114 shares of the stock were exchanged. The stock’s market cap is $562.69 million. The company has a 50-day moving average of $6.23 and a 200 day moving average of $6.56. Aurinia Pharmaceuticals has a one year low of $1.97 and a one year high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. On average, equities analysts predict that Aurinia Pharmaceuticals will post ($1.00) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/aurinia-pharmaceuticals-inc-auph-lowered-to-hold-at-vetr-inc.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUPH. FMR LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter worth approximately $42,928,000. NEA Management Company LLC grew its stake in Aurinia Pharmaceuticals by 18.2% during the first quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock worth $35,294,000 after buying an additional 740,740 shares during the period. Goldman Sachs Group Inc. grew its stake in Aurinia Pharmaceuticals by 357.3% during the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock worth $5,373,000 after buying an additional 684,816 shares during the period. Morgan Stanley grew its stake in Aurinia Pharmaceuticals by 11,061.7% during the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after buying an additional 442,138 shares during the period. Finally, Vivo Capital LLC grew its stake in Aurinia Pharmaceuticals by 68.9% during the second quarter. Vivo Capital LLC now owns 1,013,149 shares of the biotechnology company’s stock worth $6,211,000 after buying an additional 413,149 shares during the period. Institutional investors own 27.83% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.